期刊
NATURE REVIEWS DRUG DISCOVERY
卷 10, 期 10, 页码 778-792出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3551
关键词
-
资金
- Swedish Cancer Fund
- Welch Foundation (Houston, Texas, USA)
- Texas Emerging Technology Fund (Austin, Texas, USA) [300-9-1958]
The two oestrogen receptor subtypes alpha and beta are hormone-regulated modulators of intracellular signalling and gene expression. Regulation of oestrogen receptor activity is crucial not only for development and homeostasis but also for the treatment of various diseases and symptoms. Classical selective oestrogen receptor modulators are well established in the treatment of breast cancer and osteoporosis, but emerging data suggest that the development of subtype-selective ligands that specifically target either oestrogen receptor-alpha or oestrogen receptor-beta could be a more optimal approach for the treatment of cancer, cardiovascular disease, multiple sclerosis and Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据